EndoSpan

EndoSpan is a medical technology company specializing in innovative endovascular solutions for aortic arch conditions through its advanced stent graft systems. Founded in 2009 and headquartered in Herzliya, Israel, EndoSpan focuses on endovascular solutions for aortic arch treatments. The company was established by Rafi Benary, who has a background in medical device innovation. EndoSpan has successfully raised USD 15 mn in funding from investors including Sequoia Capital and Xizang Haisco Pharmaceutical Group Co.

, Ltd, marking its most recent financing round in October 2015. The company has completed 2 funding deals to date. EndoSpan specializes in innovative endovascular solutions for treating aortic arch conditions, primarily through its flagship products, the NEXUS Aortic Arch Stent Graft System and its variants, including the NEXUS DUO™ and NEXUS MULTIBRANCH devices. These custom-made stent grafts are designed with a low-profile delivery system to mitigate stroke risks associated with aortic arch procedures.

The NEXUS system enables surgeons to perform complex repairs while minimizing manipulation of aortic branches, thereby reducing the likelihood of complications such as strokes. Targeting high-risk patient populations, these products are primarily utilized by hospitals and medical institutions across Europe and select regions in Asia and New Zealand, adhering to local regulatory approvals, including CE marking for conformity. The end users of these medical devices include vascular surgeons and interventional radiologists who leverage them in clinical settings to enhance patient outcomes in aortic arch repair. EndoSpan generates revenue through direct sales of its advanced endovascular medical devices to healthcare facilities and surgical centers.

The company employs a direct-to-business model, engaging with hospitals and medical professionals who utilize their products for aortic arch surgeries. Transactions typically involve one-time purchases for the NEXUS stent graft systems based on patient needs and the specific surgical procedures planned. Given the specialized nature of these products, pricing reflects the advanced technology and custom manufacturing involved in each device, bolstered by relationships with medical professionals advocating for their flagship NEXUS products. EndoSpan plans to utilize the USD 15 mn raised in its latest financing round to enhance its product offerings and expand its market presence.

The company is focused on developing new iterations of its NEXUS systems and exploring opportunities in additional geographic regions, particularly targeting markets in Asia and New Zealand for expansion. These initiatives are aimed at increasing adoption and facilitating access to their innovative solutions for aortic arch surgeries in high-risk patient populations.